TEVA-MEDROXYPROGESTERONE TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

MEDROXYPROGESTERONE ACETATE

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

G03DA02

INN (Tên quốc tế):

MEDROXYPROGESTERONE

Liều dùng:

10MG

Dạng dược phẩm:

TABLET

Thành phần:

MEDROXYPROGESTERONE ACETATE 10MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100/500/1000

Loại thuốc theo toa:

Prescription

Khu trị liệu:

PROGESTINS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0106339006; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2011-01-18

Đặc tính sản phẩm

PRODUCT MONOGRAPH
PR
TEVA-MEDROXYPROGESTERONE
medroxyprogesterone acetate tablets USP
2.5 mg, 5 mg and 10 mg
PROGESTIN
Teva Canada Limited
Date of Revision:
30 Novopharm Court
May 12, 2014
Toronto, Ontario
M1B 2K9
Control No: 173232
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
..........................................................................................................
16
DOSAGE AND ADMINISTRATION
......................................................................................
18
OVERDOSAGE
........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL
TRIALS..................................................................................................................
26
DETAILED PHARMACOLOGY
.............................................................................................
28
TOXICOLOGY
..............